Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

"High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.

He H, Trpkov K, Martinek P, Isikci OT, Maggi-Galuzzi C, Alaghehbandan R, Gill AJ, Tretiakova M, Lopez JI, Williamson SR, Montiel DP, Sperga M, Comperat E, Brimo F, Yilmaz A, Pivovarcikova K, Michalova K, Slouka D, Prochazkova K, Hora M, Bonert M, Michal M, Hes O.

Virchows Arch. 2018 Sep 19. doi: 10.1007/s00428-018-2456-4. [Epub ahead of print]

PMID:
30232607
2.

Targeted genome fragmentation with CRISPR/Cas9 enables fast and efficient enrichment of small genomic regions and ultra-accurate sequencing with low DNA input (CRISPR-DS).

Nachmanson D, Lian S, Schmidt EK, Hipp MJ, Baker KT, Zhang Y, Tretiakova M, Loubet-Senear K, Kohrn BF, Salk JJ, Kennedy SR, Risques RA.

Genome Res. 2018 Sep 19. doi: 10.1101/gr.235291.118. [Epub ahead of print]

PMID:
30232196
3.

Contribution of Adrenal Glands to Intra-tumor Androgens and Growth of Castration Resistant Prostate Cancer.

Mostaghel EA, Zhang A, Hernandez S, Marck B, Zhang X, Tamae D, Biehl H, Tretiakova MS, Bartlett J, Burns JF, Dumpit RF, Ang LS, Matsumoto AM, Penning TM, Balk SP, Morrisey C, Corey E, True L, Nelson PS.

Clin Cancer Res. 2018 Sep 4. pii: clincanres.1431.2018. doi: 10.1158/1078-0432.CCR-18-1431. [Epub ahead of print]

PMID:
30181386
4.

Eosinophilic solid and cystic renal cell carcinoma mimicking epithelioid Angiomyolipoma: series of 4 primary tumors and 2 metastases.

Tretiakova MS.

Hum Pathol. 2018 Jun 6. pii: S0046-8177(18)30191-6. doi: 10.1016/j.humpath.2018.05.023. [Epub ahead of print]

PMID:
29885406
5.

Challenges in Pathologic Staging of Renal Cell Carcinoma: A Study of Interobserver Variability Among Urologic Pathologists.

Williamson SR, Rao P, Hes O, Epstein JI, Smith SC, Picken MM, Zhou M, Tretiakova MS, Tickoo SK, Chen YB, Reuter VE, Fleming S, Maclean FM, Gupta NS, Kuroda N, Delahunt B, Mehra R, Przybycin CG, Cheng L, Eble JN, Grignon DJ, Moch H, Lopez JI, Kunju LP, Tamboli P, Srigley JR, Amin MB, Martignoni G, Hirsch MS, Bonsib SM, Trpkov K.

Am J Surg Pathol. 2018 Sep;42(9):1253-1261. doi: 10.1097/PAS.0000000000001087.

PMID:
29878933
6.

Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum.

Tretiakova M, Mehta V, Kocherginsky M, Minor A, Shen SS, Sirintrapun SJ, Yao JL, Alvarado-Cabrero I, Antic T, Eggener SE, Picken MM, Paner GP.

Virchows Arch. 2018 May 17. doi: 10.1007/s00428-018-2371-8. [Epub ahead of print]

PMID:
29770853
7.

PAX8-Positive B-Cell Lymphoma in Adrenal Gland Masquerading as Metastatic Renal Cell Carcinoma.

Parakh R, Cheng L, Tretiakova M.

Int J Surg Pathol. 2018 Apr 1:1066896918770022. doi: 10.1177/1066896918770022. [Epub ahead of print]

PMID:
29665739
8.

Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.

Tretiakova M, Fulton R, Kocherginsky M, Long T, Ussakli C, Antic T, Gown A.

Mod Pathol. 2018 Apr;31(4):623-632. doi: 10.1038/modpathol.2017.188. Epub 2017 Dec 22.

PMID:
29271413
9.

Epitope Preservation Methods for Tissue Microarrays: Longitudinal Prospective Study.

Andeen NK, Bowman R, Baullinger T, Brooks JM, Tretiakova MS.

Am J Clin Pathol. 2017 Nov 2;148(5):380-389. doi: 10.1093/ajcp/aqx062.

PMID:
29106459
10.

Primitive Neuroectodermal Tumor and Wegener's Granulomatosis of the Kidney: A Curious Combination of Two Rare Entities.

Parakh R, Parakh S, Tretiakova M.

Case Rep Urol. 2017;2017:1750694. doi: 10.1155/2017/1750694. Epub 2017 Aug 1.

11.

Primary signet ring stromal tumor of the testis: a study of 13 cases indicating their phenotypic and genotypic analogy to pancreatic solid pseudopapillary neoplasm.

Michalova K, Michal M Jr, Kazakov DV, Sedivcova M, Hes O, Hadravsky L, Agaimy A, Tretiakova M, Bacchi C, Hartmann A, Kuroda N, Bulimbasic S, Coric M, Antic T, Michal M.

Hum Pathol. 2017 Sep;67:85-93. doi: 10.1016/j.humpath.2017.07.010. Epub 2017 Jul 21.

PMID:
28739499
12.

GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics.

Mantilla JG, Antic T, Tretiakova M.

Hum Pathol. 2017 Aug;66:152-158. doi: 10.1016/j.humpath.2017.06.016. Epub 2017 Jul 11.

PMID:
28705707
13.

Primary Renal Carcinoid with Bilateral Multiple Clear Cell Papillary Renal Cell Carcinomas.

Anderson DA, Tretiakova MS.

Case Rep Pathol. 2017;2017:9672368. doi: 10.1155/2017/9672368. Epub 2017 May 23.

14.

Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression.

Lawless M, Gulati R, Tretiakova M.

Histopathology. 2017 Sep;71(3):406-414. doi: 10.1111/his.13247. Epub 2017 Jun 27.

15.

Neoadjuvant Enzalutamide Prior to Prostatectomy.

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin ME.

Clin Cancer Res. 2017 May 1;23(9):2169-2176. doi: 10.1158/1078-0432.CCR-16-1357. Epub 2016 Nov 9.

16.

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.

Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC.

Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697.

17.

Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.

McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Am J Surg Pathol. 2016 Nov;40(11):1439-1456.

PMID:
27635949
18.

Flat Urothelial Lesions With Atypia: Interobserver Concordance and Added Value of Immunohistochemical Profiling.

Lawless ME, Tretiakova MS, True LD, Vakar-Lopez F.

Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):180-185. doi: 10.1097/PAI.0000000000000401.

PMID:
27299187
19.

A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer.

Murphy C, True L, Vakar-Lopez F, Xia J, Gulati R, Montgomery B, Tretiakova M.

Prostate. 2016 Oct;76(14):1285-92. doi: 10.1002/pros.23215. Epub 2016 Jun 8.

20.

Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):264-70. doi: 10.1038/pcan.2016.12. Epub 2016 May 3.

21.

Metastatic Renal Cell Carcinoma to the Contralateral Ureter: A Rare Phenomenon.

Dixon A, Tretiakova M, Gore J, Voelzke BB.

Urol Case Rep. 2015 Dec 10;4:36-7. doi: 10.1016/j.eucr.2015.10.005. eCollection 2016 Jan.

22.

Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators.

J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29.

23.

Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.

Macleod LC, Tykodi SS, Holt SK, Wright JL, Lin DW, Tretiakova MS, True LD, Gore JL.

Urology. 2015 Aug;86(2):262-8. doi: 10.1016/j.urology.2015.05.008. Epub 2015 Jul 18.

PMID:
26199164
24.

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.

Yu H, Liu R, Ma B, Li X, Yen HY, Zhou Y, Krasnoperov V, Xia Z, Zhang X, Bove AM, Buscarini M, Parekh D, Gill IS, Liao Q, Tretiakova M, Quinn D, Zhao J, Gill PS.

Br J Cancer. 2015 Aug 11;113(4):616-25. doi: 10.1038/bjc.2015.237. Epub 2015 Jul 16.

25.

ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.

Nguyen LT, Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I, Bolouri H, Kutyavin VI, Morrissey C, True LD, Nelson PS, Vasioukhin V.

Cancer Cell. 2015 Jun 8;27(6):797-808. doi: 10.1016/j.ccell.2015.05.005.

26.

Metastatic Treated Malignant Germ Cell Tumors: Is SALL4 a Better Marker Than Placental Alkaline Phosphatase?

Andeen NK, Tretiakova MS.

Appl Immunohistochem Mol Morphol. 2016 Mar;24(3):210-4. doi: 10.1097/PAI.0000000000000174.

PMID:
25906119
27.

Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.

Ferguson BD, Tretiakova MS, Lingen MW, Gill PS, Salgia R.

Growth Factors. 2014 Dec;32(6):202-6. doi: 10.3109/08977194.2014.980904. Epub 2014 Nov 13.

28.

Glypican 3 overexpression in primary and metastatic Wilms tumors.

Tretiakova M, Zynger DL, Luan C, Andeen NK, Finn LS, Kocherginsky M, Teh BT, Yang XJ.

Virchows Arch. 2015 Jan;466(1):67-76. doi: 10.1007/s00428-014-1669-4. Epub 2014 Nov 4.

PMID:
25366870
29.

Natural History and Malignant Transformation in Recurrent Respiratory Papillomatosis: Human Papillomavirus (HPV), Dysplasia and an Autopsy Review.

Can NT, Tretiakova MS, Taxy JB.

Fetal Pediatr Pathol. 2015 Apr;34(2):80-90. doi: 10.3109/15513815.2014.968271. Epub 2014 Oct 29. Review.

PMID:
25353697
30.

Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients.

Guo J, Tretiakova MS, Troxell ML, Osunkoya AO, Fadare O, Sangoi AR, Shen SS, Lopez-Beltran A, Mehra R, Heider A, Higgins JP, Harik LR, Leroy X, Gill AJ, Trpkov K, Campbell SC, Przybycin C, Magi-Galluzzi C, McKenney JK.

Am J Surg Pathol. 2014 Nov;38(11):1457-67. doi: 10.1097/PAS.0000000000000248.

PMID:
25093518
31.

Carbonic anhydrase IX (CAIX) does not differentiate between benign and malignant mesothelium.

Ananthanarayanan V, Tretiakova M, Husain AN, Krausz T, Antic T.

Am J Clin Pathol. 2014 Jul;142(1):82-7. doi: 10.1309/AJCP8BJ8CJXUEHZD.

PMID:
24926090
32.

Heterochromatin protein 1 expression is reduced in human thyroid malignancy.

Tretiakova MS, Bond SD, Wheeler D, Contreras A, Kocherginsky M, Kroll TG, Hale TK.

Lab Invest. 2014 Jul;94(7):788-95. doi: 10.1038/labinvest.2014.68. Epub 2014 May 19.

33.

The expression of FOXL2 in pancreatic, hepatobiliary, and renal tumors with ovarian-type stroma.

Westerhoff M, Tretiakova M, Hart J, Gwin K, Liu X, Zhou M, Yeh MM, Antic T.

Hum Pathol. 2014 May;45(5):1010-4. doi: 10.1016/j.humpath.2013.12.015. Epub 2014 Jan 17.

PMID:
24746205
34.

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.

Kanteti R, El-Hashani E, Dhanasingh I, Tretiakova M, Husain AN, Sharma S, Sharma J, Vokes EE, Salgia R.

BMC Cancer. 2014 Mar 14;14:185. doi: 10.1186/1471-2407-14-185.

35.

Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R.

Mol Cancer Ther. 2014 Mar;13(3):576-84. doi: 10.1158/1535-7163.MCT-13-0109. Epub 2013 Dec 10.

36.

Influence of histologic criteria and confounding factors in staging equivocal cases for microscopic perivesical tissue invasion (pT3a): an interobserver study among genitourinary pathologists.

Ananthanarayanan V, Pan Y, Tretiakova M, Amin MB, Cheng L, Epstein JI, Grignon DJ, Hansel DE, Jimenez RE, McKenney JK, Montironi R, Oliva E, Osunkoya AO, Rao P, Reuter VE, Ro JY, Shen SS, Srigley JR, Tsuzuki T, Yao JL, Antic T, Haber M, Taxy JB, Paner GP.

Am J Surg Pathol. 2014 Feb;38(2):167-75. doi: 10.1097/PAS.0000000000000096.

PMID:
24145655
37.

Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.

Zhao L, Antic T, Witten D, Paner GP, Taxy JB, Husain A, Gwin K, Mirza MK, Lingen MW, Tretiakova MS.

Am J Surg Pathol. 2013 Dec;37(12):1876-81. doi: 10.1097/PAS.0b013e31829e2525.

PMID:
24121175
38.

The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.

Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R, Hseu RD, Iafrate AJ, Karrison T, Ferguson MK, Husain AN, Faoro L, Vokes EE, Gill PS, Salgia R.

PLoS One. 2013 Jul 2;8(7):e67668. doi: 10.1371/journal.pone.0067668. Print 2013.

39.

Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.

Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, Wheeler DL, Husain AN, Natarajan V, Vokes EE, Singleton PA, Salgia R.

Cancer Biol Ther. 2013 Jul;14(7):679-91. doi: 10.4161/cbt.25091. Epub 2013 May 31.

40.

The different morphologies of urachal adenocarcinoma do not discriminate genomically by micro-RNA expression profiling.

Bissonnette ML, Kocherginsky M, Tretiakova M, Jimenez RE, Barkan GA, Mehta V, Sirintrapun SJ, Steinberg GD, White KP, Stricker T, Paner GP.

Hum Pathol. 2013 Aug;44(8):1605-11. doi: 10.1016/j.humpath.2013.01.008. Epub 2013 Mar 22.

PMID:
23528864
41.

High molecular weight polyethylene glycol (PEG 15-20) maintains mucosal microbial barrier function during intestinal graft preservation.

Valuckaite V, Seal J, Zaborina O, Tretiakova M, Testa G, Alverdy JC.

J Surg Res. 2013 Aug;183(2):869-75. doi: 10.1016/j.jss.2013.02.035. Epub 2013 Mar 14.

42.

Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays.

Tretiakova M, Antic T, Binder D, Kocherginsky M, Liao C, Taxy JB, Oto A.

Hum Pathol. 2013 Apr;44(4):495-502. doi: 10.1016/j.humpath.2012.06.009. Epub 2012 Oct 12.

PMID:
23069258
43.

Evaluation of microvascular density in Barrett's associated neoplasia.

Konda VJ, Hart J, Lin S, Tretiakova M, Gordon IO, Campbell L, Kulkarni A, Bissonnette M, Seewald S, Waxman I.

Mod Pathol. 2013 Jan;26(1):125-30. doi: 10.1038/modpathol.2012.146. Epub 2012 Aug 24.

44.

Differential expression of RON in small and non-small cell lung cancers.

Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R.

Genes Chromosomes Cancer. 2012 Sep;51(9):841-51. doi: 10.1002/gcc.21968. Epub 2012 May 14.

PMID:
22585712
45.

Phase II trial of temsirolimus in patients with metastatic breast cancer.

Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ.

Breast Cancer Res Treat. 2012 Nov;136(2):355-63. doi: 10.1007/s10549-011-1910-7. Epub 2012 Jan 13.

46.

MET and phosphorylated MET as potential biomarkers in lung cancer.

Tretiakova M, Salama AK, Karrison T, Ferguson MK, Husain AN, Vokes EE, Salgia R.

J Environ Pathol Toxicol Oncol. 2011;30(4):341-54.

PMID:
22181983
47.

Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis.

Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, Eggener S, Karczmar GS, Stadler WM.

AJR Am J Roentgenol. 2011 Dec;197(6):1382-90. doi: 10.2214/AJR.11.6861.

PMID:
22109293
48.

Diagnostic utility of CD10 in benign and malignant extrahepatic bile duct lesions.

Tretiakova M, Antic T, Westerhoff M, Mueller J, Himmelfarb EA, Wang HL, Xiao SY.

Am J Surg Pathol. 2012 Jan;36(1):101-8. doi: 10.1097/PAS.0b013e31822fbc95.

PMID:
21989348
49.

Laser microdissection for gene expression study of hepatocellular carcinomas arising in cirrhotic and non-cirrhotic livers.

Tretiakova M, Hart J.

Methods Mol Biol. 2011;755:233-44. doi: 10.1007/978-1-61779-163-5_19.

PMID:
21761308
50.

RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Br├Ągelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R.

Cancer Biol Ther. 2011 Jul 1;12(1):9-46. doi: 10.4161/cbt.12.1.15747. Epub 2011 Jul 1.

Supplemental Content

Loading ...
Support Center